US BANCORP \DE\ - CHINA BIOLOGIC PRODS HLDGS I ownership

Quarter-by-quarter ownership
US BANCORP \DE\ ownership history of CHINA BIOLOGIC PRODS HLDGS I
ValueSharesWeighting
Q1 2021$2,0000.0%130.0%0.00%
Q4 2020$2,000
+100.0%
130.0%0.00%
Q3 2020$1,0000.0%130.0%0.00%
Q2 2020$1,0000.0%130.0%0.00%
Q1 2020$1,000
-50.0%
130.0%0.00%
Q4 2019$2,000
+100.0%
130.0%0.00%
Q3 2019$1,000
-50.0%
13
-43.5%
0.00%
Q2 2019$2,0000.0%230.0%0.00%
Q1 2019$2,0000.0%230.0%0.00%
Q4 2018$2,0000.0%230.0%0.00%
Q3 2018$2,0000.0%230.0%0.00%
Q2 2018$2,000
-86.7%
23
-87.5%
0.00%
Q1 2018$15,000
-6.2%
184
-9.4%
0.00%
Q4 2017$16,000
-11.1%
203
+6.8%
0.00%
Q3 2017$18,0001900.00%
Other shareholders
CHINA BIOLOGIC PRODS HLDGS I shareholders Q2 2021
NameSharesValueWeighting ↓
Kite Lake Capital Management (UK) LLP 207,382$24,135,00076.46%
Maso Capital Partners Ltd 539,597$62,798,00020.20%
York Capital Management Global Advisors, LLC 1,102,163$128,270,0007.40%
HHLR ADVISORS, LTD. 2,751,200$320,185,0003.99%
Dalton Investments, Inc. 15,551$1,810,0001.14%
Athos Capital Ltd 8,290$965,0000.96%
Myriad Asset Management Ltd. 67,019$7,799,0000.94%
Temasek Holdings (Private) Ltd 990,000$115,216,0000.75%
OXFORD ASSET MANAGEMENT LLP 211,646$24,631,0000.68%
AGF Investments America Inc. 12,230$1,423,0000.47%
View complete list of CHINA BIOLOGIC PRODS HLDGS I shareholders